Dynastat | European Medicines Agency (EMA)

[ad_1]

Overview

Dynastat is a painkilling medicine for use in adults for the short-term relief of pain after an operation.

It contains the active substance parecoxib.

Dynastat is available as an injection and it can only be obtained with a prescription.

Dynastat can be given into a vein or a muscle. The first dose of 40 mg is followed by further doses of 20 or 40 mg every 6 to 12 hours, up to a maximum total dose of 80 mg a day.

For more information about using Dynastat, see the package leaflet or contact your doctor or pharmacist.

The active substance in Dynastat, parecoxib, is converted to valdecoxib in the body. Valdecoxib is a non?steroidal anti?inflammatory drug (NSAID) that belongs to the group of medicines called cyclo?oxygenase?2 (COX?2) inhibitors. It blocks the COX?2 enzyme, resulting in reduced production of prostaglandins, substances that are involved in inflammation. By reducing prostaglandins, Dynastat helps to reduce the symptoms of inflammation, including pain.

Dynastat was studied in over 2,500 adults who had surgical procedures including dental, orthopaedic (bone) and gynaecological surgery (surgery on the female reproductive system). Dynastat was compared with placebo (a dummy treatment) as well as with other painkillers such as ibuprofen, ketorolac, morphine, tramadol and valdecoxib. Dynastat was generally more effective than placebo and as effective as other painkillers. Dynastat also reduced the need for morphine.

The most common side effect with Dynastat (which may affect more than 1 in 10 people) is nausea (feeling sick). The most serious side effects (which may affect fewer than 1 in 100 people) include myocardial infarction (heart attack), severe reduction in blood pressure and allergic reactions.

Dynastat must not be used in patients who have had a serious allergic reaction to a medicine, have allergies to a class of medicines called sulfonamides or have certain illnesses including those affecting the gastrointestinal system, liver and heart. Women must not be given Dynastat during the last 3 months of pregnancy or if they are breast-feeding. It must not be used to relieve pain after certain types of heart surgery.

For the full list of side effects and restrictions of Dynastat, see the package leaflet.

Dynastat was found effective for relieving pain after surgery and its side effects are manageable.

The European Medicines Agency therefore decided that Dynastat’s benefits are greater than its risks and it can be authorised for use in the EU.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Dynastat have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Dynastat are continuously monitored. Side effects reported with Dynastat are carefully evaluated and any necessary action taken to protect patients.

Dynastat received a marketing authorisation valid throughout the EU on 22 March 2002.

English (EN)
(159.13 KB – PDF)

First published: 15/04/2009Last updated: 13/07/2020

View

English (EN)
(1.57 MB – PDF)

First published: 10/10/2024

View

Product information

English (EN)
(527.28 KB – PDF)

First published: 08/01/2010Last updated: 05/03/2025

View

Latest procedure affecting product information:
N/0000248141

04/03/2025

This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

Product information documents contain:

summary of product characteristics (annex I);
manufacturing authorisation holder responsible for batch release (annex IIA);
conditions of the marketing authorisation (annex IIB);
labelling (annex IIIA);
package leaflet (annex IIIB).

English (EN)
(74.59 KB – PDF)

First published: 15/11/2005Last updated: 24/08/2012

View

Product details

Name of medicine: Dynastat
Active substance: parecoxib sodium
International non-proprietary name (INN) or common name: parecoxib
Therapeutic area (MeSH): Pain, Postoperative
Anatomical therapeutic chemical (ATC) code: M01AH04

Pharmacotherapeutic group

Antiinflammatory and antirheumatic products
Coxibs

Therapeutic indication

For the short-term treatment of postoperative pain in adults.

[ad_2]

Source link

Subscribe now

To access premium content

Ubisoft To Develop Blockchain Games, Enjin’s $100 Million Fund

All About Play to Earn With Crypto Games (P2E)

Blockchain Gaming Industry & 5 Crypto Games to Watch

Ethereum Still Leads The Way in Blockchain Gaming

What is Binamon? Ready For Launch On August 28

Binapet Review: Breeding BSC Play-to-Earn Game

The Galaxy of Lemuria Review – Play To Earn MMORPG

BLAST Premier 2022 – Betting Tips and Schedule

Zendodo Party Review: Where NFTs Meets DeFi on WAX

BLAST Premier 2022 – Betting Tips and Schedule

Is Overwatch League Getting Outsourced A Good Thing?

Genesis Worlds Interview With CEO Jason Cassidy

Dreamverse NFT Festival: Interview With Twobadour

Inside Axie Infinity With Jihoz – Growth Lead